Last edition
News about "Saudi Nod Positions OneSource for Growth in GLP-1 "
Saudi Nod Positions OneSource for Growth in GLP-1 Therapies
OneSource Specialty Pharma Limited has secured approval from the Saudi Food and Drug Authority (SFDA) for its generic version of Ozempic (semaglutide), enabling the company to begin commercialisation in Saudi Arabia through an exclusive partnership with Hikma Pharmaceuticals.
Saudi Nod Positions OneSource For Growth In GLP-1 | 11/02/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members